Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmican Q
- Development stage
- Unknown
- Lead developer
- Jeil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telmican Q is a fixed-dose combination (FDC) therapy developed by Jeil Pharmaceutical Co., Ltd. for the simultaneous management of hypertension and hyperlipidemia (dyslipidemia). It integrates three active pharmaceutical ingredients: rosuvastatin, telmisartan, and amlodipine. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers LDL cholesterol and triglycerides while increasing HDL cholesterol. Telmisartan is an angiotensin II receptor blocker (ARB) that promotes vasodilation and reduces blood pressure by selectively antagonizing the AT1 receptor. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the influx of calcium ions into vascular smooth muscle, leading to peripheral vasodilation and further blood pressure reduction. This triple combination is designed to simplify complex treatment regimens, thereby improving medication adherence and cardiovascular outcomes in patients with multiple risk factors.
- Brand names
- Telmican Q
- Other names
- rosuvastatin + telmisartan + amlodipineTelmisartan/Amlodipine/Rosuvastatin
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Telmican Q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telmican Q.